Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Radiopharm Theranostics Limited ( (AU:RAD) ) just unveiled an announcement.
Radiopharm Theranostics Limited has announced the establishment of an At-the-Market (ATM) equity facility in the U.S., enabling the sale of American Depositary Shares (ADSs) to raise capital for product development and corporate needs. The ATM facility, which permits flexible, incremental fundraising based on prevailing market conditions, is a strategic move aiming to leverage U.S. capital markets, potentially raising up to $22.4 million initially with a wider $50 million ceiling over three years, enhancing the company’s financial flexibility in line with market trends.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company developing innovative radiopharmaceutical products for diagnostic and therapeutic applications in oncology, targeting areas of high unmet medical need. The company focuses on peptides, small molecules, and monoclonal antibodies for cancer treatment and is conducting Phase 1 and Phase 2 clinical trials across various solid tumor types. It is publicly listed on both the ASX and Nasdaq exchanges.
Average Trading Volume: 11,532,554
Technical Sentiment Signal: Buy
Current Market Cap: A$102.8M
See more insights into RAD stock on TipRanks’ Stock Analysis page.